Glutamate and anxiety

European Neuropsychopharmacology

Volumn 14, Issue 3, 2004, Pages 175-183

  Bergink, Veerle ^a   Van Megen, Harold J G M ^a   Westenberg, Herman G M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Animal models; Anxiety; Fear conditioning; Glutamate; Therapeutic

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST; ANXIOLYTIC AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; EGLUMETAD; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR AGONIST; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; GLYCINE; KAINIC ACID RECEPTOR; METABOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE;

ANXIETY DISORDER; BEHAVIOR DISORDER; BRAIN FUNCTION; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG TOLERABILITY; HUMAN; IDENTITY; NEUROBIOLOGY; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PERCEPTION DISORDER; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; STROKE;

ANIMALS; ANXIETY; ANXIETY DISORDERS; DISEASE MODELS, ANIMAL; GLUTAMIC ACID; HUMANS; NEUROBIOLOGY; RECEPTORS, GLUTAMATE;

EID: 1642634565     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(03)00100-7     Document Type: Review

References (82)

1. Anthony E.W., Nevins M.E. Anxiolytic-like effects of N-methyl-D- aspartate-associated glycine receptor ligands in the rat potentiated startle test. Eur. J. Pharmacol. 250:1993;317-324.
2. Baron B.M., Harrison B.L., Kehne J.H., et al. Pharmacologic characterization of MDL 105,519, an NMDA receptor glycine site antagonist. Eur. J. Pharmacol. 323:1997;181-192.
3. Bennet D.A., Amrick C.L. 2 amino-7-phosphonoheptanoatic acid produces discriminative stimuli and anticonflict effects similar to diazepam. Life Sci. 39:1986;2455-2461.
4. Benvenga M.J., Leander J.D., Ornstein P.L. Anxiolytic effect of the competitive AMPA antagonist 215490 in a pigeon punished responding model. Soc. Neurosci. 19:1993;293.
5. Bliss T.V.P., Collingridge G.L. A synaptic model of memory: long term potentiation in the hippocampus. Nature. 361:1993;31-39.
6. Brann D.W., Mahesh V.B. Excitatory amino acids, function and significance in reproduction and neuroendocrine regulation. Front. Neuroendocrinol. 15:1994;3-49.
7. Brenner M., Haass A., Jacobi P., et al. Amantine sulphate in treating Parkinson's disease: clinical effects, psychometric tests and serum concentration. J. Neurol. 236:1989;153-156.
8. Brodkin J., Busse C., Sukoff S.J., et al. Anxiolytic-like activity of the mGluR5 antagonist MPEP a comparison with diazepam and buspirone. Pharmacol. Biochem. Behav. 73:(2):2002;359-366.
9. Charney D.S., Nagy L.M., Brenner D., et al. Neurobiological mechanisms of human anxiety. Fogel B.S., Schiffer R.B., Rao S.M. Neuropsychiatry. 1996;Williams and Wilkins, Baltimore, MD.
10. Collingridge G.L., Lester R.A. Excitatory amine acid receptors in the vertebrate central nervous system. Pharmacol. Rev. 41:1989;143-210.
11. Corbett R., Dunn R.W. Effects of HA-966 on conflict, social interaction and plus maze behaviour. Drug Dev. Res. 24:1991;201.
12. Corbett R. Effects of 5,7 dichlorokynurenic acid on conflict, social interaction and plus maze behaviour. Neuropharmacology. 32:(5):1993;461-466.
13. Cotman C.W., Kahle J.S., Miler S.E., et al. Excitatory amino acid neurotransmission. Bloom F.E., Kupfer D.J. Psychopharmacology: the Fourth Generation of Progress. 1995;Raven Press, New York.
14. Criswel H.E., Knapp D.J., Overstreet D.H., Breese G.R. Effects of ethanol, chordiazepoxide and MK-801 on performance in the elevated plus maze and on locomotor activity. Alcohol. Clin. Exp. Res. 18:1994;596.
15. Dannhardt G., Kohl B.K. The glycine site on the NMDA receptor: structure-activity relationships and possible therapeutic applications. Curr. Med. Chem. 5:(4):1998;253-256.
16. Danysz W., Parsons C.G., Bresink I., Quack G. Glutamate in CNS disorders. Drug News Perspect. 8:1995;261-277.
17. Davidson R.J. Anxiety and affective style: role of prefrontal cortex and amygdala. Biol. Psychiatry. 51:(1):2002;68-80.
18. Davis M., Rainnie D., Cassel M. Neurotransmission in the rat amygdala related to fear and anxiety. Trends Neurosci. 17:1994;208-214.
19. Davis M. Neurobiology of fear responses: the role of the amygdala. J. Neuropsychiatry Clin. Neurosci. 9:1997;382-402.
20. Dawson G.R., Tricklebank M.D. Use of the elevated plus maze in the search for novel anxiolytic agents. Trends Pharmacol. Sci. 16:1995;33-36.
21. Dunn R.W., Corbett R., Fielding S. Effects of 5-HT1a receptor agonists and NMDA receptor antagonists in the social interaction test and the elevated plus maze. Eur. J. Pharmacol. 169:1989;1-10.
22. Dunn R.W., Flanagan D.M., Martin L.L., et al. Stereoselective R-(+) enantiomer of HA-966 displays anxiolytic effects in rodents. Eur. J. Pharmacol. 214:1992;207.
23. Fraser C.M., Cooke M.J., Fisher A., et al. Interactions between ifenprodil and dizolcipne on mouse behaviour in models of anxiety and working memory. Eur. Neuropsychopharmacol. 6:(4):1996;311-316.
24. Graeff F.G. Role of 5-HT in defensive behavior and anxiety. Rev. Neurosci. 4:1993;181-211.
25. Grotta J., Clark W., Coull B., et al. Safety and tolerability of the glutamate antagonist CGS 19755 in patients with acute ischemic stroke. Results of a phase IIa randomized trial. Stroke. 26:1995;602-605.
26. Haefely W. The GABA-benzodiazepine interaction fifteen years later. Neurochem. Res. 15:(2):1990;169-174.
27. Helton D.R., Tizzano J.P., Monn J.A., et al. Anxiolytic and Side-effect profile of LY354740: a potent highly selective orally active agonist for group II metabotropic glutamate receptors. J. Pharmacol. Exp. Ther. 284:1997;651-660.
28. Hollmann M., Heinemann S. Cloned glutamate receptors. Annu. Rev. Neurosci. 17:1994;31-108.
29. Javitt D.C., Zukin R.C. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. 148:(10):1991;1301-1308.
30. Jessa M., Nazar M., Bidzinsky A., Plaznik A. The effect of repeated administration of diazepam, MK-801 and CGP 37849 on rat behaviour in two models of anxiety. Eur. Neuropsychopharmacol. 6:1996;55-61.
31. Johnston G.A.R. GABAa receptor pharmacology. Pharmacol. Ther. 69:(3):1996;173-198.
32. Jones B.J., Blackburn T.P. The medical benefit of 5-HT research. Pharmacol. Biochem. Behav. 71:(4):2002;555-568.
33. Kaczmarek L., Kossut M., Skangielkramska J. Glutamate receptors in cortical plasticity: molecular and cellular biology. Physiol. Rev. 77:1997;217-255.
34. Karcz M., Kubich M., Liljequist S. Evidence for an anxiogenic action of AMPA receptor antagonists in the plus-maze test. Eur. J. Pharmacol. 279:1995;171-177.
35. Karcz M., Jessa M., Nazar M., et al. Anxiolytic activity of glycine B antagonists and partial agonists-no relation to intrinsic activity in patch clamp. Neuropharmacology. 36:(10):1997;1355-1367.
36. Kehne J.H., McCloskey T.C., Baron B.M., Chi E.M., et al. NMDA receptor complex antagonists have potential anxiolytic effects as measured with separation-induced ultrasonic vocalisation. Eur. J. Pharmacol. 193:1991;283-292.
37. Kehne J.H., Baron B.M., Harrison B.L., et al. MDL 100, 458 and MDL 102,288: two potent and selective glycine receptor antagonists with different functional profiles. Eur. J. Pharmacol. 284:1995;109-118.
38. Kim M., McGaugh J.L. Effects of intra-amygdala injections of NMDA receptor antagonists on acquisition and retention of inhibitory avoidance. Brain Res. 58:1992;35-48.
39. Klepstad P., Maurset A., Moberg E.R., et al. Evidence of a role for NMDA receptors in pain perception. Eur. J. Pharmacol. 187:1990;513-518.
40. Klodzinska A., Chojnacka-Wojcik E., Palucha A., et al. Potential anti-anxiety, anti-addictive effects of LY354740, a selective group II glutamate metabotropic receptors agonist in animal models. Neuropharmacology. 38:1999;1831-1839.
41. Koek W., Colpaert F.C. Use of a conflict procedure in pigeons to characterize anxiolytic drug activity: evaluation of NMDA antagonists. Life Sci. 49:1991;37-42.
42. Kotlinska J., Liljequist S. The putative AMPA receptor antagonist, LY326325, produces anxiolytic effects without altering locomotor activity in rats. Pharmacol. Biochem. Behav. 60:1998;119-124.
43. Kotlinska J., Liljequist S. A characterization of anxiolytic like action induced by the novel NMDA/glycine site antagonist L-701,324. Psychopharmacology (Berlin). 135:(2):1998;175-181.
44. Krystal J.H., Laurence P.K., Seibyl J.P., et al. Subanesthetic effect of the non-competitive NMDA antagonist, ketamine, in humans. Psychomimetic, perceptual, cognitive and neuroendocrine responses. Arch. Gen. Psychiatry. 51:1994;199-214.
45. Krystal J.H., D'Souza D.C., Ismene L., et al. NMDA agonists and antagonists as probes of glutamergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv. Rev. Psychiatry. 7:(3):1999;125-143.
46. LeDoux J.E. Emotion, memory and the brain. Sci. Am. 4:1994;32-39.
47. LeDoux J.E. Fear and the brain: where have we been and where are we going? Biol. Psychiatry. 44:1998;1229-1238.
48. Luby E.D., Cohen B.D., Rosenbaum G., et al. Study of a new schizophrenic-mimetic drug: Sernyl. AMA Arch. Neurol. Psychiatry. 81:1959;363-369.
49. Maren S. Synaptic transmission and plasticity in the amygdala. Mol. Neurobiol. 13:1996;1-22.
50. Miserandino M.J.D., Sananes C.B., Melia K.R., Davis M. Blocking of acquisition but not expression of conditioned fear-potentiated startle by NMDA antagonists in the amygdala. Nature. 345:1990;716-718.
51. Nakanishi S. Molecular diversity of glutamate receptors and implications for brain function. Science. 258:1992;597-603.
52. Ninan P.T., Insel T.M., Cohen R.M., et al. Benzodiazepine receptor-mediated experimental anxiety in primates. Science. 218:1982;1332-1334.
53. Ninan P.T. The functional anatomy, neurochemistry, and pharmacology of anxiety. J. Clin. Psychiatry. 60:(22):1999;12-17.
54. Ohishi H., Shigemoto R., Nakanishi S., Mizuno N. Distribution of the mRNA for a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat. Neuroscience. 53:1993;1009-1018.
55. Parsons C.G., Danysz W., Quack G. Glutamate in CNS disorder as a target for drug development: an update. Drug News Perspect. 11:(9):1999;523-569.
56. Parsons C.G., Danysz W., Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology. 38:1999;735-767.
57. Pilc A., Klodzinska A., Branski P., et al. Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats. Neuropharmacology. 43:(2):2002;181-187.
58. Pin J.P., Duvoisin R. The metabotropic glutamate receptors: structure and functions. Neuropharmacology. 34:1995;1-26.
59. Pin J.P., De Colle C., Bessis A.S., Acher F. New perspectives for the development of selective metabotropic glutamate receptor ligands. Eur. J. Pharmacol. 375:(1-3):1999;277-294.
60. Plaznik A., Palejko W., Nazar M., Jessa M. Effects of antagonists at the NMDA receptor complex in two models of anxiety. Eur. Neuropsychopharmacol. 4:1994;503-512.
61. Porter J.H., Wiley J.L., Balster R.L. Effects of phencyclidine-like drugs on punished behaviour in rats. J. Pharmacol. Exp. Ther. 248:1989;997-1002.
62. Przegalinsky E., Tatarczynska E., Deren-Wesolek A., et al. Anticonflict effect of a competitive NMDA receptor antagonist and a partial agonist at strychine-insensitive glycine receptors. Pharmacol. Biochem. Behav. 54:(1):1996;73-77.
63. Rogan T.C., Staubli U.V., LeDoux J.E. Fear conditioning induces associative long-term potentiation in the amygdala. Nature. 390:1997;604-607.
64. Silvestre J.S., Nadal R., Pallares M., Ferre N. Acute effects of ketamine in the holeboard, the elevated plus maze, and the social interaction test in Wistar rats. Depress. Anxiety. 5:1997;29-33.
65. Salt T.E., Eaton S.A. Functions of ionotropic and metabotropic glutamate receptors in sensory transmission in the mammalian thalamus. Progr. Neurobiol. 48:1995;55-72.
66. Sajdyk T.J., Shekhar A. Excitatory aminoacid receptors in the basolateral amygdala regulate anxiety responses in the social interaction test. Brain Res. 764:1997;262-264.
67. Sanger D.J., Jackson A. Effects of phencyclidine and other N-methyl-D-aspartate antagonists on the schedule controlled behaviour. J. Pharmacol. Exp. Ther. 248:1989;1215-1221.
68. Schoepp D.D., Conn P.J. Metabotropic glutamate receptors in brain function and pathology. Trends Pharmacol. Sci. 14:1993;13-20.
69. Schoepp D.D., Jane D.E., Monn J.A. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology. 38:(10):1999;1431-1476.
70. Shepard J.D., Barron K.W., Myers D.A. Corticosterone delivery to the amygdala increases corticotropin-releasing factor mRNA in the central amygdaloid nucleus and anxiety-like behavior. Brain Res. 861:(2):2000;288-295.
71. Shekhar A., Keim S.R. LY354740, a potent group II metapbotropic glutamate receptor agonist prevents lactate-induced panic-like response in panic-prone rats. Neuropharmacology. 39:2000;1139-1146.
72. Spooren W.P., Vassout A., Neijt H.C., et al. Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J. Pharmacol. Exp. Ther. 295:2000;1267-1275.
73. Stephens D.N., Meldrun B.S., Weidmann R., et al. Does the excitatory amino acid receptor antagonist 2-APH exhibit anxiolytic activity? Psychopharmacology. 90:1986;166-169.
74. Tatarczynska E., Klodzinska A., Chojnacka-Wojcik E., et al. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br. J. Pharmacol. 132:2001;1423-1430.
75. Trullas R., Jackson B., Skolnick P. Anxiolytic properties pr 1-aminocyclopropanecarboxylic acid, a ligand at strychnine-insensitive glycine receptors. Pharmacol. Biochem. Behav. 34:1989;313-316.
76. Vry De J., Benz U., Schreiber R., Traber J. Shock-induced ultrasonic vocalisation in young adult rats: a model for testing putative anxiolytic drugs. Eur. J. Pharmacol. 249:1993;331-339.
77. Walker D.L., Davis M. The role of amygdala glutamate receptors in fear learning, fear-potentiated startle, and extinction. Pharmacol. Biochem. Behav. 71:2002;379-392.
78. Watkins J., Collingridge G. Phenylglycine derivates as antagonist of metabotropic glutamate receptors. Trends Pharmacol. Sci. 15:1994;333-342.
79. Wiley J.L. Behavioral pharmacology of NMDA antagonists: implications for the study and pharmacotherapy of anxiety and schizophrenia. Exp. Clin. Psychopharmacol. 5:(4):1997;365-374.
80. Wiley J.L., Cristello A.F., Balster R.L. Effects of site selective NMDA receptor antagonists in an elevated plus model of anxiety in mice. Eur. J. Pharmacol. 294:1995;101-107.
81. Willetts J., Clissold T.L., Hartmann R.R., et al. Behavioral pharmacology of NPC 17742, a competitive NMDA antagonist. J. Pharmacol. Exp. Ther. 265:1994;1055-1062.
82. Xie Z., Commissaris L. Anxiolytic-like effects of the noncompetitive NMDA antagonist MK801. Pharmacol. Biochem. Behav. 43:1992;471-477.